PTGX
Protagonist Therapeutics Inc
139.90$
-0.7%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | +324.9% | -98.4% | +12.2% | +3,550.0% | -83.4% | -80.4% | -15.0% | +57.8% | +657.9% | +278.7% | – | |
| – | +0.6% | -1.4% | +8.8% | – | – | – | – | – | – | +8.2% | – | – | |
| – | – | +324.9% | -98.4% | +12.2% | +3,550.0% | -83.4% | -80.4% | -15.0% | +57.8% | +652.5% | +281.5% | – | |
| – | -5.8% | +16.7% | -0.6% | +7.3% | -3.0% | +2.8% | +3.2% | +8.0% | +15.9% | +0.8% | -10.0% | – | |
| – | +5.1% | +85.2% | -36.7% | +7.6% | -11.9% | +31.1% | -10.1% | +5.5% | +2.7% | +16.1% | -4.7% | – | |
| – | -3.6% | +31.6% | -11.7% | +7.4% | -4.9% | +8.6% | -0.1% | +7.5% | +13.0% | +3.1% | -8.2% | – | |
| – | – | +795.1% | -118.8% | – | – | -115.2% | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | +670.7% | -114.9% | – | – | -108.7% | – | – | – | – | +7,138.7% | – | |
| – | – | – | -120.3% | – | – | – | – | – | – | -325.5% | – | – | |
| – | – | +658.5% | -114.8% | – | – | -108.9% | – | – | – | – | +4,204.8% | – | |
| – | – | +648.8% | -114.1% | – | – | -108.5% | – | – | – | – | +6,057.4% | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.